Are your mobile phone and continuous glucose monitoring application compatible?

IF 3.4 3区医学 Q1 HEALTH POLICY & SERVICES

Health Policy and Technology Pub Date : 2025-02-08 DOI:10.1016/j.hlpt.2025.100991

Katrine Bovién Gørlitz , Mia Uldum Tolstrup , Sofie Husted Wilken , Cathrine Bell , Klavs Würgler Hansen

{"title":"Are your mobile phone and continuous glucose monitoring application compatible?","authors":"Katrine Bovién Gørlitz , Mia Uldum Tolstrup , Sofie Husted Wilken , Cathrine Bell , Klavs Würgler Hansen","doi":"10.1016/j.hlpt.2025.100991","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><div>Patients who use mobile apps for continuous glucose monitoring (CGM) often disregard the official mobile phone compatibility list. This study aimed to describe the user proportion whose mobile phones are not on the compatibility list (unlisted) and compare their glycaemic metrics with those of users with compatible phones.</div></div><div><h3>Methods</h3><div>All users of the Freestyle Libre2 CGM and LibreLink app connected to our clinic were evaluated if a glucose data download was available within three months (n = 248). We checked the mobile name appearing on the LibreView report with the manufacturer's list of compatible devices. Glycaemic metrics and adjustment for loss of signal alarms were recorded from LibreView.</div></div><div><h3>Results</h3><div>A total of 197 persons were using a compatible phone (79.4 %). The median active CGM time was 96 % (IQR: 91-98) for persons with compatible phones and 96 % (IQR: 89-98) for persons with an unlisted phone (p = 0.76). The time in range (glucose 3.9-10.0 mmol/l) for persons with a compatible phone was 55.9 ± 20.9 %; for users with an unlisted phone, 55.3 ± 21.8 % (p = 0.85). The loss-of-signal alarm was more frequently enabled for users with unlisted phones (45.0 %) than for users with compatible phones (24.0 %) (p < 0.01).</div></div><div><h3>Conclusion</h3><div>Persons who use unlisted phones have a similar, high active CGM time as persons with compatible phones. The relationship between compatibility status and enabling of the loss-of-signal alarm remains unknown.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 2","pages":"Article 100991"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Policy and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221188372500019X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aim

Patients who use mobile apps for continuous glucose monitoring (CGM) often disregard the official mobile phone compatibility list. This study aimed to describe the user proportion whose mobile phones are not on the compatibility list (unlisted) and compare their glycaemic metrics with those of users with compatible phones.

Methods

All users of the Freestyle Libre2 CGM and LibreLink app connected to our clinic were evaluated if a glucose data download was available within three months (n = 248). We checked the mobile name appearing on the LibreView report with the manufacturer's list of compatible devices. Glycaemic metrics and adjustment for loss of signal alarms were recorded from LibreView.

Results

A total of 197 persons were using a compatible phone (79.4 %). The median active CGM time was 96 % (IQR: 91-98) for persons with compatible phones and 96 % (IQR: 89-98) for persons with an unlisted phone (p = 0.76). The time in range (glucose 3.9-10.0 mmol/l) for persons with a compatible phone was 55.9 ± 20.9 %; for users with an unlisted phone, 55.3 ± 21.8 % (p = 0.85). The loss-of-signal alarm was more frequently enabled for users with unlisted phones (45.0 %) than for users with compatible phones (24.0 %) (p < 0.01).

Conclusion

Persons who use unlisted phones have a similar, high active CGM time as persons with compatible phones. The relationship between compatibility status and enabling of the loss-of-signal alarm remains unknown.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Health Policy and Technology Medicine-Health Policy

CiteScore

9.20

自引率

3.30%

发文量

审稿时长

88 days

期刊介绍： Health Policy and Technology (HPT), is the official journal of the Fellowship of Postgraduate Medicine (FPM), a cross-disciplinary journal, which focuses on past, present and future health policy and the role of technology in clinical and non-clinical national and international health environments. HPT provides a further excellent way for the FPM to continue to make important national and international contributions to development of policy and practice within medicine and related disciplines. The aim of HPT is to publish relevant, timely and accessible articles and commentaries to support policy-makers, health professionals, health technology providers, patient groups and academia interested in health policy and technology. Topics covered by HPT will include: - Health technology, including drug discovery, diagnostics, medicines, devices, therapeutic delivery and eHealth systems - Cross-national comparisons on health policy using evidence-based approaches - National studies on health policy to determine the outcomes of technology-driven initiatives - Cross-border eHealth including health tourism - The digital divide in mobility, access and affordability of healthcare - Health technology assessment (HTA) methods and tools for evaluating the effectiveness of clinical and non-clinical health technologies - Health and eHealth indicators and benchmarks (measure/metrics) for understanding the adoption and diffusion of health technologies - Health and eHealth models and frameworks to support policy-makers and other stakeholders in decision-making - Stakeholder engagement with health technologies (clinical and patient/citizen buy-in) - Regulation and health economics